A systematic review and meta-analysis evaluated the association between corticosteroid therapy, mortality, and infectious complications in adults with severe non-COVID-19 pneumonia or acute respiratory distress syndrome (ARDS). The…
Author: admin
-

Was Harry referencing Trump in joke for Late Show sketch?
The Duke of Sussex appeared to joke about US President Donald Trump in an appearance on The Late Show With Stephen Colbert.
Prince Harry appeared in a US TV sketch with Colbert, where he auditioned as himself for a “Christmas prince” role in a…
Continue Reading
-

Pantone Color of the Year 2026 gives neutral (again)
As 2025’s cultural retrospectives begin to trickle in (read: Spotify Wrapped or Oxford’s word of the year), Pantone is not to be outdone.
The famed color factory on Thursday, Dec. 4, released its shade of the upcoming year, or perhaps more…
Continue Reading
-

Jon M. Chu Says AI Couldn’t Have Made One of Wicked’s Best Moments
If there’s anyone who understands the importance of viral marketing, it’s Wicked: For Good director Jon M. Chu.
At WIRED’s Big Interview event in San Francisco, the onetime YouTuber and Crazy Rich Asians director said that working with acts…
Continue Reading
-

Assessing UiPath’s Valuation After Recent AI Automation Expansion and Choppy Share Price Moves
-
If you have been wondering whether UiPath is a hidden bargain or a value trap at around $14.86 a share, you are not alone. This article is going to walk through exactly what the numbers are really saying.
-
Despite being down about 6.4% over the last month and roughly 3.1% over the past year, the stock is still up 9.3% over the last week and 14.9% year to date, which signals that sentiment around its long term potential is far from settled.
-
Recent headlines have focused on UiPath expanding its AI powered automation offerings and strengthening key partnerships, underlining its push to stay at the center of the automation trend. At the same time, market commentary has highlighted both rising competition and shifting expectations for high growth software names, helping explain the stock’s choppy price action.
-
On our framework, UiPath scores a 3/6 valuation check. This suggests it looks undervalued on some metrics but not convincingly cheap across the board. Next we will unpack the main valuation approaches investors are using and then finish with a more holistic way to make sense of what UiPath might really be worth.
Find out why UiPath’s -3.1% return over the last year is lagging behind its peers.
A Discounted Cash Flow model projects a company’s future cash flows and then discounts them back to today’s dollars to estimate what the business is worth right now.
For UiPath, the latest twelve month Free Cash Flow is about $318.9 million. Analysts and internal estimates see this rising steadily, with projected Free Cash Flow reaching roughly $695.4 million by 2035, based on a 2 Stage Free Cash Flow to Equity framework. Simply Wall St uses explicit analyst forecasts for the next few years and then extrapolates further out to build a 10 year cash flow curve.
When these future cash flows are discounted back to today, the model arrives at an intrinsic value of about $18.10 per share. Compared with the current share price around $14.86, the DCF suggests UiPath is trading at roughly a 17.9% discount to its estimated fair value. On this basis, the shares appear attractively priced according to the model.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests UiPath is undervalued by 17.9%. Track this in your watchlist or portfolio, or discover 908 more undervalued stocks based on cash flows.
PATH Discounted Cash Flow as at Dec 2025 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for UiPath.
For a growing software business like UiPath that is still prioritizing scale over bottom line profits, the Price to Sales ratio is often a more reliable yardstick than earnings based metrics. Revenue tends to be more stable and less affected by short term swings in investment spending, making it a cleaner way to compare valuation.
Continue Reading
-
-

Pneumonia-related Bacterial Enzyme Causes Heart Conditions
A pneumococcal enzyme, zmpB, is a key factor in some pneumonia patients develop serious heart complications.
RT’s Three Key Takeaways:
- Bacterial Driver of Cardiac Complications – Researchers identified a pneumococcal…
Continue Reading
-

A SAARC alternate?
.
The eight-member SAARC, dysfunctional now for more than a decade, is in need of a new lease of life. It cannot be resurrected in its present edifice as…
Continue Reading
-
Ovarian Tumor Treatment Resistance and Immune Modulation Tied to Claudin‑4 – Inside Precision Medicine
- Ovarian Tumor Treatment Resistance and Immune Modulation Tied to Claudin‑4 Inside Precision Medicine
- From Lab to Clinic: CU Anschutz Launches Phase 1 Clinical Trial of Promising Combination Therapy for Resistant Ovarian Cancer CU Anschutz…
Continue Reading
-

M5 MacBook Pro Hits Record Low $1,499 with 24GB RAM
Looking at the latest MacBook Pro deal, it’s hard not to get excited about what Apple is offering right now. The M5 MacBook Pro with 24GB of RAM has dropped to a record-low $1,499, which is a substantial $300 discount that’s genuinely worth…
Continue Reading
-
A couple and their daughter use a telescope to observe the last supermoon of 2025, known as the Cold Moon, in Aguimes – Reuters Connect
- A couple and their daughter use a telescope to observe the last supermoon of 2025, known as the Cold Moon, in Aguimes Reuters Connect
- Last supermoon of 2025 to be visible in Pakistan tonight, tomorrow Dawn
- ‘Cold Supermoon’ 2025: Why the final…
Continue Reading
